AIMS/HYPOTHESIS: The expression of IFNbeta in beta cells results in accelerated type 1 diabetes. The REG family of beta cell proliferation factors have been described as autoantigens in autoimmune diabetes. The aim of this study was to determine the effect of IFNbeta on Reg expression, and the implications of this in terms of autoimmunity. METHODS: Reg gene expression was determined in islets from non-obese diabetic (NOD) RIP-HuIFNbeta mice by cDNA microarray, quantitative real-time PCR and immunohistochemistry. The effect of IFNbeta on Reg1 and Reg2 expression was assessed in the NOD insulinoma cell line NIT-1. IL-6, known to induce Reg expression, was measured in the insulitis microenvironment. Morphological studies were carried out to determine islet enlargement in this model. RESULTS: Reg2 was upregulated in islets from the NOD RIP-HuIFNbeta mice at the onset of the autoimmune attack. IFNbeta upregulates Reg1 and Reg2 genes in NIT-1 cells. The expression of Il6 was increased in islets from transgenic mice and in NIT-1 cells exposed to HuIFNbeta. Moreover, islets from transgenic mice were enlarged compared with those from wild-type mice. CONCLUSIONS/ INTERPRETATION: Reg overexpression correlates well with the acceleration of diabetes in this model. The upregulation of Reg suggests that islets try to improve hyperglycaemia by regenerating the cells lost in the autoimmune attack. Reg expression is regulated by several factors such as inflammation. Therefore, the overexpression of an IFNbeta-induced autoantigen (REG) in the islets during inflammation might contribute to the premature onset of diabetes.
AIMS/HYPOTHESIS: The expression of IFNbeta in beta cells results in accelerated type 1 diabetes. The REG family of beta cell proliferation factors have been described as autoantigens in autoimmune diabetes. The aim of this study was to determine the effect of IFNbeta on Reg expression, and the implications of this in terms of autoimmunity. METHODS: Reg gene expression was determined in islets from non-obese diabetic (NOD) RIP-HuIFNbetamice by cDNA microarray, quantitative real-time PCR and immunohistochemistry. The effect of IFNbeta on Reg1 and Reg2 expression was assessed in the NOD insulinoma cell line NIT-1. IL-6, known to induce Reg expression, was measured in the insulitis microenvironment. Morphological studies were carried out to determine islet enlargement in this model. RESULTS:Reg2 was upregulated in islets from the NOD RIP-HuIFNbetamice at the onset of the autoimmune attack. IFNbeta upregulates Reg1 and Reg2 genes in NIT-1 cells. The expression of Il6 was increased in islets from transgenic mice and in NIT-1 cells exposed to HuIFNbeta. Moreover, islets from transgenic mice were enlarged compared with those from wild-type mice. CONCLUSIONS/ INTERPRETATION: Reg overexpression correlates well with the acceleration of diabetes in this model. The upregulation of Reg suggests that islets try to improve hyperglycaemia by regenerating the cells lost in the autoimmune attack. Reg expression is regulated by several factors such as inflammation. Therefore, the overexpression of an IFNbeta-induced autoantigen (REG) in the islets during inflammation might contribute to the premature onset of diabetes.
Authors: A Sekikawa; H Fukui; S Fujii; A Nanakin; N Kanda; Y Uenoyama; T Sawabu; H Hisatsune; T Kusaka; S Ueno; H Nakase; H Seno; T Fujimori; T Chiba Journal: Gut Date: 2005-05-24 Impact factor: 23.059
Authors: Heather J Galipeau; Nestor E Rulli; Jennifer Jury; Xianxi Huang; Romina Araya; Joseph A Murray; Chella S David; Fernando G Chirdo; Kathy D McCoy; Elena F Verdu Journal: J Immunol Date: 2011-09-12 Impact factor: 5.422
Authors: Linda Yip; Leon Su; Deqiao Sheng; Pearl Chang; Mark Atkinson; Margaret Czesak; Paul R Albert; Ai-Ris Collier; Shannon J Turley; C Garrison Fathman; Rémi J Creusot Journal: Nat Immunol Date: 2009-08-09 Impact factor: 25.606
Authors: Lorella Marselli; Jeffrey Thorne; Sonika Dahiya; Dennis C Sgroi; Arun Sharma; Susan Bonner-Weir; Piero Marchetti; Gordon C Weir Journal: PLoS One Date: 2010-07-13 Impact factor: 3.240
Authors: K Yoshimoto; T Fujimoto; A Itaya-Hironaka; T Miyaoka; S Sakuramoto-Tsuchida; A Yamauchi; M Takeda; T Kasai; K Nakagawara; A Nonomura; S Takasawa Journal: Clin Exp Immunol Date: 2013-10 Impact factor: 4.330